















**Table S1.** Chemical structures and suspected toxicities of the studied oral antineoplastics.

Medicines under additional monitoring	Chemical Structure <sup>1</sup>	Suspected toxicity
Alectinib		<ul style="list-style-type: none"> <li>• Gastrointestinal disorders</li> <li>• Liver disorders</li> <li>• Lung disorders</li> <li>• Kidney disorders</li> </ul>
Cabozantinib		<ul style="list-style-type: none"> <li>• Mucosites</li> <li>• Hypertension</li> </ul>
Entrectinib		<ul style="list-style-type: none"> <li>• Hypotension</li> <li>• Vomiting</li> </ul>
Ixazomib		<ul style="list-style-type: none"> <li>• Haematological disorders</li> </ul>
Lenalidomide		<ul style="list-style-type: none"> <li>• Anorexia</li> <li>• Haematological disorders</li> <li>• Neurological disorders</li> </ul>
Lorlatinib		<ul style="list-style-type: none"> <li>• Dyslipidemia</li> </ul>
Niraparib		-
Osimertinib		<ul style="list-style-type: none"> <li>• Paronychia</li> </ul>
Palbociclib		<ul style="list-style-type: none"> <li>• Haematological disorders</li> </ul>
Ribociclib		<ul style="list-style-type: none"> <li>• Haematological disorders</li> </ul>
Trametinib + Dabrafenib		<ul style="list-style-type: none"> <li>• Fever</li> </ul>
Vandetanib		<ul style="list-style-type: none"> <li>• QT prolongation</li> <li>• Skin disorders</li> </ul>
Venetoclax		<ul style="list-style-type: none"> <li>• Haematological disorders</li> </ul>
Trifluridine + tipiracil		<ul style="list-style-type: none"> <li>• Gastrointestinal disorders</li> <li>• Haematological disorders</li> <li>• Proteinuria</li> </ul>

<sup>1</sup>All the chemical structures images were retrieved from the website <https://pubchem.ncbi.nlm.nih.gov/>. [Accessed 25 Mar 2023].